DEPUTY Prime Minister Teo Chee Hean has conferred Singapore's Distinguished Partner in Progress (DPIP) Award on Novartis International and STATS ChipPAC in recognition of their contributions to the nation's economic growth, and their commitment to promoting social and community interests.
"Both Novartis and STATS ChipPAC have continually adapted to change and pursued growth opportunities in a sustainable manner," said Mr Teo at the awards ceremony. "Their investments and strategic business activities here have created many good jobs for Singaporeans. The two companies have continually innovated and transformed their operations and business activities, mirroring Singapore's economic development over the years."
With a headcount of over 1,500 in Singapore, Novartis is among the top three investors in Singapore's biomedical sciences industry. Aside from its Asia-Pacific headquarters, the global healthcare firm has four manufacturing facilities in Singapore.
Local company STATS ChipPAC provides semiconductor packaging and test services for a range of semiconductor devices for communications, consumer, and computing applications. It employs about 3,000 staff across its global headquarters, research & development centre, and manufacturing activities here. STATS ChipPAC has also committed to investing a further US$500 million over the next three years to expand its operations in Singapore.
"Their presence in Singapore has enabled them to continue to transform their operations, pursue new technologies and growth areas, as well as manage their regional and global operations," said Leo Yip, chairman of the Economic Development Board (EDB), congratulating the two companies.
Since 1991, 29 companies have been conferred the DPIP Award, which is administered by the EDB.

DEPUTY Prime Minister Teo Chee Hean has conferred Singapore's Distinguished Partner in Progress (DPIP) Award on Novartis International and STATS ChipPAC in recognition of their contributions to the nation's economic growth, and their commitment to promoting social and community interests.

"Both Novartis and STATS ChipPAC have continually adapted to change and pursued growth opportunities in a sustainable manner," said Mr Teo at the awards ceremony. "Their investments and strategic business activities here have created many good jobs for Singaporeans. The two companies have continually innovated and transformed their operations and business activities, mirroring Singapore's economic development over the years."

With a headcount of over 1,500 in Singapore, Novartis is among the top three investors in Singapore's biomedical sciences industry. Aside from its Asia-Pacific headquarters, the global healthcare firm has four manufacturing facilities in Singapore.

Local company STATS ChipPAC provides semiconductor packaging and test services for a range of semiconductor devices for communications, consumer, and computing applications. It employs about 3,000 staff across its global headquarters, research & development centre, and manufacturing activities here. STATS ChipPAC has also committed to investing a further US$500 million over the next three years to expand its operations in Singapore.

"Their presence in Singapore has enabled them to continue to transform their operations, pursue new technologies and growth areas, as well as manage their regional and global operations," said Leo Yip, chairman of the Economic Development Board (EDB), congratulating the two companies.

Since 1991, 29 companies have been conferred the DPIP Award, which is administered by the EDB.